New gentle chemo combo after transplant aims to stop leukemia relapse

NCT ID NCT06129734

Recruiting now Disease control Sponsor: Benjamin Tomlinson Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a low-dose, weekly chemotherapy combination (decitabine and venetoclax) given after a bone marrow transplant can help prevent high-risk myeloid cancers like acute myeloid leukemia from coming back. About 20 participants will receive the treatment for up to one year, alongside standard post-transplant care. The main goals are to see if this approach is safe and practical, and whether it improves survival without causing severe side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELOID MALIGNANCY

Contacts and locations

Locations

Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center
RECRUITING

Cleveland, Ohio, 44106, United States
University Hospitals Seidman Cancer, Case Comprehensive Cancer Center
RECRUITING

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.